Eledon Pharmaceuticals (ELDN) Competitors

Nuvation Bio (NYSE:NUVB) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.

Do analysts recommend NUVB or ELDN?

Nuvation Bio presently has a consensus target price of $8.75, suggesting a potential upside of 343.04%. Eledon Pharmaceuticals has a consensus target price of $12.50, suggesting a potential upside of 313.22%. Given Nuvation Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Nuvation Bio is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Eledon Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in NUVB or ELDN?

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 5.1% of Nuvation Bio shares are owned by insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in NUVB or ELDN?

Nuvation Bio received 26 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. Likewise, 81.82% of users gave Nuvation Bio an outperform vote while only 73.68% of users gave Eledon Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Nuvation Bio	Outperform Votes 54 81.82%	Underperform Votes 12 18.18%
Eledon Pharmaceuticals	Outperform Votes 28 73.68%	Underperform Votes 10 26.32%

Does the media refer more to NUVB or ELDN?

In the previous week, Nuvation Bio had 8 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 9 mentions for Nuvation Bio and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.89 beat Nuvation Bio's score of 1.22 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvation Bio	Positive
Eledon Pharmaceuticals	Very Positive

Is NUVB or ELDN more profitable?

Nuvation Bio's return on equity of -21.89% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	N/A	-21.89%	-17.86%
Eledon Pharmaceuticals	N/A	-189.99%	-28.17%

Which has preferable earnings & valuation, NUVB or ELDN?

Nuvation Bio has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$7.87M	84.96	-$75.80M	-$2.26	-0.87
Eledon Pharmaceuticals	N/A	N/A	-$116.54M	-$2.36	-1.28

Which has more volatility and risk, NUVB or ELDN?

Nuvation Bio has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.

Summary

Nuvation Bio beats Eledon Pharmaceuticals on 15 of the 17 factors compared between the two stocks.